Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE Patents

Shire plc SHPGY announces that it has filed lawsuits in the U.S. District Court for the District of New Jersey against Roxane Laboratories, Inc., and in the U.S. District Court for the Central District of California against Watson Laboratories, Inc., respectively, for infringement of certain of Shire's VYVANSE patents. The lawsuits were initiated in response to Abbreviated New Drug Applications filed by each of Roxane and Watson seeking FDA approval to market and sell generic versions of all currently approved doses of VYVANSE.